7H-pyrimidino<5,4-c>carbazole | 59943-51-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 7H-pyrimidino<5,4-c>carbazole
• 英文别名: 7H-Pyrimido[5,4-c]carbazole
• CAS: 59943-51-0
• 化学式: C₁₄H₉N₃
• 分子量: 219.246
• InChiKey: HJGHAQFHGFDSCJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7H-pyrimidino<5,4-c>carbazole 在 potassium permanganate 、 lithium 作用下， 以 乙醚 、 丙酮 为溶剂， 反应 7.0h， 生成 n-butyl-4 7H-pyrimidino<5,4-c>carbazole
  参考文献：
  名称：

  Lancelot, Jean-Charles; Gazengel, Jean-Marie; Robba, Max, Chemical and pharmaceutical bulletin, 1983, vol. 31, # 8, p. 2652 - 2661

  摘要：

  DOI：
• 作为产物：
  描述：

  dihydro-6,7 5H-pyrimidino<5,4-c>carbazole 在 potassium permanganate 作用下， 以 丙酮 为溶剂， 反应 18.0h， 以29%的产率得到7H-pyrimidino<5,4-c>carbazole
  参考文献：
  名称：

  Lancelot, Jean-Charles; Gazengel, Jean-Marie; Robba, Max, Chemical and pharmaceutical bulletin, 1983, vol. 31, # 8, p. 2652 - 2661

  摘要：

  DOI：

文献信息

• APPLICATION OF N-BENZYL TRYPTANTHRIN DERIVATIVE AS TRYPTOPHAN DIOXYGENASE (TDO) INHIBITOR
  申请人：FUDAN UNIVERSITY

  公开号：US20200101075A1

  公开（公告）日：2020-04-02

  The present invention provides an application of N-benzyl tryptanthrin derivative as tryptophan dioxygenase (TDO) inhibitor, and more specifically an application of N-benzyl tryptanthrin derivative or a pharmaceutically acceptable salt thereof. Said derivative has a structural general formula as represented by formula 1, wherein each group is defined as in the specification. The derivative of the present invention has a good TDO inhibiting activity and can be used to prepare a treatment for diseases associated with TDO activity and expression.

  本发明提供了N-苄基色胺酸三氮杂吲哚衍生物作为色氨酸双氧酶(TDO)抑制剂的应用，更具体地是N-苄基色胺酸三氮杂吲哚衍生物或其药用可接受的盐的应用。所述衍生物具有由式1表示的结构通用公式，其中每个基团如规范中所定义。本发明的衍生物具有良好的TDO抑制活性，可用于制备与TDO活性和表达相关的疾病的治疗。
• Use of tryptanthrin compounds for immune potentiation
  申请人：Chiron Corporation

  公开号：US20040241192A1

  公开（公告）日：2004-12-02

  The invention provides immunostimulatory compositions and methods of administration thereof. Also provided are methods of administering a tryptanthrin compound in an effective amount to enhance the immune response of a subject to an antigen. Also provided are methods of administering an effective amount of a tryptanthrin to stimulate the immune response in a subject for the treatment of cancer. Further provided are methods of administering a tryptanthrin compounds as an immunotherapeutic in the treatment of infectious diseases.

  该发明提供了免疫刺激性组合物及其给药方法。还提供了一种给予色胺酸酸衍生物有效量的方法，以增强受体对抗原的免疫反应。还提供了一种给予有效量色胺酸酸衍生物的方法，以刺激受体的免疫反应，用于治疗癌症。此外，还提供了一种给予色胺酸酸衍生物作为免疫治疗剂治疗传染病的方法。
• USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION
  申请人：VALIANTE Nicholas M.

  公开号：US20120244182A1

  公开（公告）日：2012-09-27

  The invention provides immunostimulatory compositions and methods of administration thereof. Also provided are methods of administering a tryptanthrin compound in an effective amount to enhance the immune response of a subject to an antigen. Also provided are methods of administering an effective amount of a tryptanthrin to stimulate the immune response in a subject for the treatment of cancer. Further provided are methods of administering a tryptanthrin compounds as an immunotherapeutic in the treatment of infectious diseases.

  本发明提供了免疫刺激组合物及其给药方法。还提供了一种给予吲哚丹宁化合物有效量的方法，以增强受体对抗原的免疫反应。还提供了一种给予有效量的吲哚丹宁化合物的方法，以刺激受体对癌症的免疫反应。此外，还提供了将吲哚丹宁化合物作为免疫治疗剂治疗传染病的方法。
• Methods and pharmaceutical compositions for treating microbiome dysregulations associated with circadian clock disruption
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

  公开号：US11364219B2

  公开（公告）日：2022-06-21

  The present invention relates to the treatment of microbiome dysregulations. Said dysregulations may subsequently contribute to the development of several chronic diseases. Thus characterization of new post-biotic compounds inducing beneficial changes on host-microbiota interactions may be highly desirable. The inventors showed that Nlrp6 diurnally coordinates cyclical adaptation of the gut microbiota diversity to epithelial plasticity in response to a treatment with a Csnk2 inhibitor. The invention therefore relates to an inhibitor of Csnk2, for use in the treatment of microbiome dysregulations notably associated with circadian clock disruption. Said inhibitor may be selected among chemically synthesized or natural selective Csnk2 inhibitors such as flavones.

  本发明涉及微生物组失调的治疗。这些失调可能会导致多种慢性疾病的发生。因此，对能诱导宿主-微生物群相互作用发生有益变化的新生物后化合物进行表征可能是非常可取的。本发明者的研究表明，Nlrp6 在使用 Csnk2 抑制剂治疗的情况下，会周期性地协调肠道微生物群多样性对上皮可塑性的适应。因此，本发明涉及一种 Csnk2 抑制剂，用于治疗主要与昼夜节律紊乱有关的微生物组失调。所述抑制剂可选择化学合成或天然选择性 Csnk2 抑制剂，如黄酮类。
• ROBBA M.; BOUTAMINE N., C. R. ACAD. SCI. <CHDC-AQ>, 1976, C282, NO 15, 671-673
  作者：ROBBA M.、 BOUTAMINE N.

  DOI：——

  日期：——